(BLUE) stock downgraded by Bank of America and J.P. Morgan after the company's Q3 2024 results. Read more here.

In celebration of its 100th year as an institution open to the public, the Morgan Library and Museum has launched the ...

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday and set a price ...

JP Morgan has recently reduced bluebird bio Inc (BLUE) stock to Neutral rating, as announced on August 15, 2024, according to Finviz. Earlier, on December 11, 2023, HSBC Securities had reduced the ...

On Tuesday, bluebird bio Inc (BLUE) stock saw a decline, ending the day at $0.39 which represents a decrease of $-0.02 or -4.88% from the prior close of $0.41. The stock opened at $0.4 and touched a ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Neurocrine (NBIX – Research Report) on November 6 and set a price target of ...

Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked Robert F.

(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...

Investing.com -- Following Donald Trump's recent election victory, JPMorgan (NYSE:JPM)'s quantitative analysts anticipate ...